GlassScriptPhysician profile
Fatima M Khan
NPI 1407070667
$8,095.25
in general payments reported to CMS, 2019-2025
19 companies · $1,578 in 2025
The $1,578 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $383 · 2021: $686 · 2022: $1,531 · 2023: $1,499 · 2024: $1,460 · 2025: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,477 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,477.49 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,134.95 | 2019-2025 | |
| Pfizer INC. | $871.03 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $687.46 | 2019-2025 | |
| Cumberland Pharmaceuticals, INC. | $386.21 | 2020-2022 | |
| Amgen INC. | $375.87 | 2019-2025 | Tavneos, Evenity, Otezla |
| Glaxosmithkline, LLC. | $367.28 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $286.61 | 2019-2024 | Taltz |
| Janssen Biotech, INC. | $256.06 | 2019-2024 | Tremfya |
| Ucb, INC. | $160.89 | 2023-2025 | Cimzia, Bimzelx |
| Novo Nordisk INC | $124.97 | 2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $101.91 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $91.11 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $59.99 | 2023 | Acthar |
| Medexus Pharma, INC. | $59.88 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $36.37 | 2025 | Dupixent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $28.92 | 2023 | Saphnelo |
| Depuy Synthes Sales INC. | $24.90 | 2023 | Orthovisc |
| Abbott Laboratories | $21.12 | 2019 | |
| Sandoz INC. | $19.72 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatima Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.